{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:56:39Z","timestamp":1740135399883,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["UG1EY030833"],"award-info":[{"award-number":["UG1EY030833"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The World Health Organization (WHO) recommends annual mass azithromycin distribution until districts drop below 5% prevalence of trachomatous inflammation\u2014follicular (TF). Districts with very low TF prevalence may have little or no transmission of the ocular strains of <jats:italic>Chlamydia trachomatis<\/jats:italic> that cause trachoma, and additional rounds of mass azithromycin distribution may not be useful. Here, we describe the protocol for a randomized controlled trial designed to evaluate whether mass azithromycin distribution can be stopped prior to the current WHO guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The Azithromycin Reduction to Reach Elimination of Trachoma (ARRET) study is a 1:1 community randomized non-inferiority trial designed to evaluate whether mass azithromycin distribution can be stopped in districts with baseline prevalence of TF under 20%. Communities in Maradi, Niger are randomized after baseline assessment either to continued annual mass azithromycin distribution or stopping annual azithromycin distribution over a 3-year period. We will compare the prevalence of ocular <jats:italic>C. trachomatis<\/jats:italic> (primary outcome), TF and other clinical signs of trachoma, and serologic markers of trachoma after 3\u00a0years. We hypothesize that stopping annual azithromycin distribution will be non-inferior to continued annual azithromycin distributions for all markers of trachoma prevalence and transmission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The results of this trial are anticipated to provide potentially guideline-changing evidence for when mass azithromycin distributions can be stopped in low TF prevalence areas.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial\u00a0registration number<\/jats:title>\n                <jats:p>This study is registered at clinicaltrials.gov (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04185402\">NCT04185402<\/jats:ext-link>). Registered December 4, 2019; prospectively registered pre-results.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-020-01776-4","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T20:05:26Z","timestamp":1609963526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Azithromycin Reduction to Reach Elimination of Trachoma (ARRET): study protocol for a cluster randomized trial of stopping mass azithromycin distribution for trachoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Abdou","family":"Amza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boubacar","family":"Kadri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beido","family":"Nassirou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed M.","family":"Arzika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariana","family":"Austin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanice","family":"Nyatigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elodie","family":"Lebas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin F.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Lietman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine E.","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"1776_CR1","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1056\/NEJMoa040979","volume":"351","author":"AW Solomon","year":"2004","unstructured":"Solomon AW, Holland MJ, Alexander NDE, et al. Mass Treatment with Single-Dose Azithromycin for Trachoma. N Engl J Med. 2004;351:1962\u201371.","journal-title":"N Engl J Med"},{"key":"1776_CR2","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jama.295.10.1142","volume":"295","author":"JD Chidambaram","year":"2006","unstructured":"Chidambaram JD, Alemayehu W, Melese M, et al. Effect of a Single Mass Antibiotic Distribution on the Prevalence of Infectious Trachoma. JAMA. 2006;295:1142\u20136.","journal-title":"JAMA"},{"unstructured":"World Health Organization. WHO Alliance for the Global Elimination of Trachoma by 2020: progress report on elimination of trachoma. 2018. Wkly Epidemiol Rec 2019; 29: 317\u201328.","key":"1776_CR3"},{"issue":"4","key":"1776_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/09286586.2019.1597129","volume":"26","author":"A Amza","year":"2019","unstructured":"Amza A, Kadri B, Nassirou B, et al. Community-level Association between Clinical Trachoma and Ocular Chlamydia Infection after Mass Azithromycin Distribution in a Mesoendemic Region of Niger. Ophthalmic Epidemiol. 2019;26(4):231\u20137.","journal-title":"Ophthalmic Epidemiol"},{"key":"1776_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/09286586.2014.884600","volume":"21","author":"KJ Ray","year":"2014","unstructured":"Ray KJ, Zhou Z, Cevallos V, et al. Estimating Community Prevalence of Ocular Chlamydia trachomatis Infection using Pooled Polymerase Chain Reaction Testing. Ophthalmic Epidemiol. 2014;21:86\u201391.","journal-title":"Ophthalmic Epidemiol"},{"key":"1776_CR6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/jamaophthalmol.2014.335","volume":"132","author":"RN Maamari","year":"2014","unstructured":"Maamari RN, Ausayakhun S, Margolis TP, Fletcher DA, Keenan JD. Novel telemedicine device for diagnosis of corneal abrasions and ulcers in resource-poor settings. JAMA Ophthalmol. 2014;132:894\u20135.","journal-title":"JAMA Ophthalmol"},{"key":"1776_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/inthealth\/ihz035","author":"BM Snyder","year":"2019","unstructured":"Snyder BM, Si\u00e9 A, Tapsoba C, et al. Smartphone photography as a possible method of post-validation trachoma surveillance in resource-limited settings. Int Health. 2019. DOI:https:\/\/doi.org\/10.1093\/inthealth\/ihz035.","journal-title":"Int Health"},{"unstructured":"Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for assessment of trachoma and its complications. Bull World Health Organ 1987;477\u201383.","key":"1776_CR8"},{"key":"1776_CR9","doi-asserted-by":"publisher","first-page":"e1873-10","DOI":"10.1371\/journal.pntd.0001873","volume":"6","author":"EB Goodhew","year":"2012","unstructured":"Goodhew EB, Priest JW, Moss DM, et al. CT694 and pgp3 as Serological Tools for Monitoring Trachoma Programs. PLoS Negl Trop Dis. 2012;6:e1873-10.","journal-title":"PLoS Negl Trop Dis"},{"key":"1776_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4269\/ajtmh.2011.11-0056","volume":"85","author":"B Ayele","year":"2011","unstructured":"Ayele B, Gebre T, House JI, et al. Adverse Events after Mass Azithromycin Treatments for Trachoma in Ethiopia. Am J Trop Med Hyg. 2011;85:291\u20134.","journal-title":"Am J Trop Med Hyg"},{"key":"1776_CR11","doi-asserted-by":"publisher","first-page":"696","DOI":"10.4269\/ajtmh.18-0781","volume":"100","author":"T Astale","year":"2019","unstructured":"Astale T, Sata E, Zerihun M, et al. Self-Reported Side Effects following Mass Administration of Azithromycin to Eliminate Trachoma in Amhara, Ethiopia: Results from a Region-Wide Population-Based Survey. Am J Trop Med Hyg. 2019;100:696\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"1776_CR12","doi-asserted-by":"publisher","first-page":"e0006950","DOI":"10.1371\/journal.pntd.0006950","volume":"12","author":"CE Oldenburg","year":"2018","unstructured":"Oldenburg CE, Arzika AM, Maliki R, et al. Safety of azithromycin in infants under six months of age in Niger: A community randomized trial. PLoS Negl Trop Dis. 2018;12:e0006950.","journal-title":"PLoS Negl Trop Dis"},{"key":"1776_CR13","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S0140-6736(09)60323-8","volume":"373","author":"JI House","year":"2009","unstructured":"House JI, Ayele B, Porco TC, et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomisedtrial. Lancet. 2009;373:1111\u20138.","journal-title":"Lancet"},{"key":"1776_CR14","doi-asserted-by":"publisher","first-page":"100309","DOI":"10.1016\/j.conctc.2018.100309","volume":"13","author":"L Clifton","year":"2019","unstructured":"Clifton L, Birks J, Clifton DA. Comparing different ways of calculating sample size for two independent means: A worked example. Contemp Clin Trials Commun. 2019;13:100309.","journal-title":"Contemp Clin Trials Commun"},{"key":"1776_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09286586.2017.1293693","volume":"26","author":"N Wilson","year":"2019","unstructured":"Wilson N, Goodhew B, Mkocha H, et al. Evaluation of a Single Dose of Azithromycin for Trachoma in Low-Prevalence Communities. Ophthalmic Epidemiol. 2019;26:1\u20136.","journal-title":"Ophthalmic Epidemiol"},{"doi-asserted-by":"crossref","unstructured":"Oldenburg CE. One Size Does Not Fit All: Achieving Trachoma Control by 2030. Am J Trop Med Hyg 2019; 1\u20132.","key":"1776_CR16","DOI":"10.4269\/ajtmh.19-0684"},{"key":"1776_CR17","doi-asserted-by":"publisher","first-page":"e1000377-9","DOI":"10.1371\/journal.pmed.1000377","volume":"7","author":"AH Skalet","year":"2010","unstructured":"Skalet AH, Cevallos V, Ayele B, et al. Antibiotic Selection Pressure and Macrolide Resistance in Nasopharyngeal Streptococcus pneumoniae: A Cluster-Randomized Clinical Trial. PLoS Med. 2010;7:e1000377-9.","journal-title":"PLoS Med"},{"key":"1776_CR18","first-page":"30444","volume":"S1437-3099","author":"K O\u2019Brien","year":"2018","unstructured":"O\u2019Brien K, Emerson P, Hooper PJ, et al. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. Lancet Infect Dis. 2018;S1437-3099:30444\u20134.","journal-title":"Lancet Infect Dis"},{"key":"1776_CR19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1086\/655697","volume":"51","author":"S Haug","year":"2010","unstructured":"Haug S, Lakew T, Habtemariam G, et al. The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Clin Infect Dis. 2010;51:571\u20134.","journal-title":"Clin Infect Dis"},{"key":"1776_CR20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.inhe.2011.06.001","volume":"3","author":"B Ayele","year":"2011","unstructured":"Ayele B, Belay T, Gebre T, et al. Association of community antibiotic consumption with clinically active trachoma in rural Ethiopia. Int Health. 2011;3:282\u20138.","journal-title":"Int Health"},{"key":"1776_CR21","doi-asserted-by":"publisher","first-page":"8805","DOI":"10.1167\/iovs.11-8074","volume":"52","author":"B Munoz","year":"2011","unstructured":"Munoz B, Stare D, Mkocha H, Gaydos C, Quinn T, West SK. Can Clinical Signs of Trachoma Be Used after Multiple Rounds of Mass Antibiotic Treatment to Indicate Infection? Invest Ophthalmol Vis Sci. 2011;52:8805\u20136.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1776_CR22","first-page":"e0005080-7","volume":"10","author":"SD Nash","year":"2018","unstructured":"Nash SD, Stewart AEP, Zerihun M, et al. Ocular Chlamydia trachomatis Infection Under the Surgery, Antibiotics, Facial Cleanliness, and Environmental Improvement Strategy in Amhara, Ethiopia, 2011\u20132015. Clin Infect Dis. 2018;10:e0005080-7.","journal-title":"Clin Infect Dis"},{"key":"1776_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41467-018-07852-0","volume":"9","author":"A Pinsent","year":"2018","unstructured":"Pinsent A, Solomon AW, Bailey RL, et al. The utility of serology for elimination surveillance of trachoma. Nat Commun. 2018;9:25\u20138.","journal-title":"Nat Commun"},{"key":"1776_CR24","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaophthalmol.2017.3062","volume":"135","author":"SK West","year":"2017","unstructured":"West SK, Zambrano AI, Sharma S, et al. Surveillance Surveys for Reemergent Trachoma in Formerly Endemic Districts in Nepal From 2 to 10 Years After Mass Drug Administration Cessation. JAMA Ophthalmol. 2017;135:1141\u20136.","journal-title":"JAMA Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01776-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-020-01776-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-020-01776-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T21:36:21Z","timestamp":1609968981000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-020-01776-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1776"],"URL":"https:\/\/doi.org\/10.1186\/s12886-020-01776-4","relation":{},"ISSN":["1471-2415"],"issn-type":[{"type":"electronic","value":"1471-2415"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"8 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was reviewed and approved by the Institutional Review Board at the University of California, San Francisco and Le Comit\u00e9 National d\u2019Ethique pour la Recherche en Sant\u00e9 (National Research Ethics Committee) in Niamey, Niger. Verbal informed consent is obtained from each participant or their guardian for those under 18\u00a0years of age, and written informed consent is obtained from each community\u2019s leader once they have agreed that their community may participate in the trial. Verbal, rather than written, informed consent is obtained due to low literacy rates in the study communities. Both institutional review boards approved the verbal consent procedure. The trial is conducted under the tenets of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}